BofA Securities analyst Travis Steed maintains $Boston Scientific (BSX.US)$ with a buy rating, and sets the target price at $100.
According to TipRanks data, the analyst has a success rate of 64.7% and a total average return of 8.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
The company Boston Scientific has been identified as possessing the 'best in medtech growth' according to an analyst. This perspective is based on the belief that the company's growth trajectory is solid and that it will maintain its double-digit revenue expansion. With 'one of the fullest pipelines in medtech,' it is expected that a significant portion of Boston Scientific's revenue growth will contribute positively to its profit margins.
The firm holds the view that Boston Scientific will surpass the market's third-quarter expectations and is likely to elevate its forecasts once more. The company is currently witnessing considerable momentum, bolstered by several pivotal factors such as Farapulse, which is consistently gaining market share over both RF and cryo technologies.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Travis Steed維持$波士頓科學 (BSX.US)$買入評級,目標價100美元。
根據TipRanks數據顯示,該分析師近一年總勝率為64.7%,總平均回報率為8.0%。
此外,綜合報道,$波士頓科學 (BSX.US)$近期主要分析師觀點如下:
一位分析師稱,波士頓科學公司被確定爲 「醫療技術增長最快的公司」。這種觀點基於這樣的信念,即公司的增長軌跡穩健,並將保持兩位數的收入增長。憑藉 「醫療技術領域最完善的渠道之一」,預計波士頓科學收入增長的很大一部分將爲其利潤率做出積極貢獻。
該公司認爲,波士頓科學將超出市場第三季度的預期,並可能再次提高其預測。在Farapulse等幾個關鍵因素的推動下,該公司目前勢頭強勁,與射頻和低溫技術相比,Farapulse的市場份額持續增加。
提示:
TipRanks為獨立第三方,提供金融分析師的分析數據,並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議,僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級,分析師星級代表分析師所有推薦的過往表現,通過分析師的總勝率和平均回報率综合計算得出,星星越多,則該分析師過往表現越優異,最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否,取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合,並根據評級變化對組合進行調整,在近一年中該投資組合所獲得的回報率。